Experienced in Acute Myeloblastic Leukemia without Maturation

Dr. Shannon L. Schmidt

Hematology Oncology | Hematology | Oncology
Thedacare Incorporated
333 N Green Bay Rd, 
Neenah, WI 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
16 Years of Experience
Experienced in Acute Myeloblastic Leukemia without Maturation
Thedacare Incorporated
333 N Green Bay Rd, 
Neenah, WI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Shannon Schmidt is a Hematologist Oncology specialist and a Hematologist in Neenah, Wisconsin. Dr. Schmidt has been practicing medicine for over 16 years and is rated as an Experienced provider by MediFind in the treatment of Acute Myeloblastic Leukemia without Maturation. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, B-Cell Lymphoma, Angiosarcoma, and Bone Marrow Aspiration. Dr. Schmidt is currently accepting new patients.

Her clinical research consists of participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Medical College Of Wisconsin, 2009
Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in WI
Hospital Affiliations
Thedacare Regional Medical Center - Appleton Inc
Thedacare Regional Med Ctr - Neenah
Thedacare Medical Center-Waupaca
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Aspirus Arise Health
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Common Ground Healthcare
  • OTHER COMMERCIAL
Common Ground Healthcare Cooperative
  • EPO
  • PPO
Dean Health
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Network Health
  • HMO
Quartz
  • HMO
  • POS
  • PPO
Quartz Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Security Health
  • EPO
  • HMO
  • INDEMNITY
  • POS
TeamCare
  • OTHER COMMERCIAL
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 21 Less Insurance Carriers -

Locations

THEDACARE INCORPORATED
333 N Green Bay Rd, Neenah, WI 54956
Other Locations
THEDACARE INCORPORATED
491 S Washburn St, Suite 100, Oshkosh, WI 54904
THEDACARE INCORPORATED
1405 S Mill St, New London, WI 54961
THEDACARE INCORPORATED
600 N Westhaven Dr, Oshkosh, WI 54904
THEDACARE INCORPORATED
2005 Midway Rd, Menasha, WI 54952
THEDACARE INCORPORATED
4480 W Spencer St, Appleton, WI 54915

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib
The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib
Enrollment Status: Recruiting
Publish Date: January 13, 2025
Intervention Type: Other, Biological, Drug
Study Drugs: Trastuzumab Emtansine, Tucatinib
Study Phase: Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently With Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer
A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently With Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 26, 2025
Intervention Type: Drug, Procedure, Radiation, Other
Study Drug: Olaparib
Study Phase: Phase 2
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
Enrollment Status: Active_not_recruiting
Publish Date: April 18, 2025
Intervention Type: Procedure, Biological, Drug, Radiation
Study Drugs: Docetaxel, Nab-Paclitaxel, Paclitaxel, Pertuzumab, Trastuzumab, Trastuzumab Emtansine
Study Phase: Phase 2
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
View 4 Less Clinical Trials
Similar Doctors
Advanced in Acute Myeloblastic Leukemia without Maturation
Dr. Kevin L. Mortara
Hematology Oncology | Hematology | Oncology
Advanced in Acute Myeloblastic Leukemia without Maturation
Dr. Kevin L. Mortara
Hematology Oncology | Hematology | Oncology
1580 Commanche Ave, 
Green Bay, WI 
 (27.9 miles away)
920-435-8326
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Kevin Mortara is a Hematologist Oncology specialist and a Hematologist in Green Bay, Wisconsin. Dr. Mortara is rated as an Advanced provider by MediFind in the treatment of Acute Myeloblastic Leukemia without Maturation. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Chronic Lymphocytic Leukemia (CLL), Paget Disease of the Breast, and Endoscopy. Dr. Mortara is currently accepting new patients.

Advanced in Acute Myeloblastic Leukemia without Maturation
Dr. Jasleen Randhawa
Hematology | Oncology
Advanced in Acute Myeloblastic Leukemia without Maturation
Dr. Jasleen Randhawa
Hematology | Oncology

Agnesian Healthcare Inc

480 E Division St, 
Fond Du Lac, WI 
 (29.0 miles away)
920-926-4100
Languages Spoken:
English
See accepted insurances

Jasleen Randhawa is a Hematologist and an Oncologist in Fond Du Lac, Wisconsin. Dr. Randhawa is rated as an Advanced provider by MediFind in the treatment of Acute Myeloblastic Leukemia without Maturation. Her top areas of expertise are Castleman Disease, Multicentric Castleman Disease (MCD), Unicentric Castleman Disease (UCD), Acute Myeloblastic Leukemia without Maturation, and Bone Marrow Aspiration.

Advanced in Acute Myeloblastic Leukemia without Maturation
Dr. Steven Bettag
Oncology | Hematology
Advanced in Acute Myeloblastic Leukemia without Maturation
Dr. Steven Bettag
Oncology | Hematology

Sheboygan Physicians Group S.C.

1621 N Taylor Dr, Suite 100, 
Sheboygan, WI 
 (47.3 miles away)
920-458-7433
Languages Spoken:
English
See accepted insurances

Steven Bettag is an Oncologist and a Hematologist in Sheboygan, Wisconsin. Dr. Bettag is rated as an Advanced provider by MediFind in the treatment of Acute Myeloblastic Leukemia without Maturation. His top areas of expertise are Paget Disease of the Breast, Familial Colorectal Cancer, Lung Cancer, and Myelodysplastic Syndrome (MDS).

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Schmidt's expertise for a condition
ConditionClose
    View All 10 Distinguished Conditions
    View All 29 Advanced Conditions
    View All 136 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile